These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10097952)

  • 1. [Decreased rate of progression and induction of tumor-specific immune response by adjuvant immunotherapy in stage IV melanoma].
    Enk AH; Wölfel T; Knop J
    Hautarzt; 1999 Feb; 50(2):103-8. PubMed ID: 10097952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
    Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
    Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
    Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
    J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
    Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
    Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
    Hauschild A
    Hautarzt; 1996 Jan; 47(1):67-8. PubMed ID: 8835010
    [No Abstract]   [Full Text] [Related]  

  • 13. [Experiences with therapy of stage IV metastatic malignant melanoma with "Legha Protocol" polychemoimmunotherapy].
    Fischer B; Knop J; Enk AH
    Hautarzt; 2002 Jun; 53(6):393-9. PubMed ID: 12132295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].
    Terheyden P; Kämpgen E; Rünger TM; Bröcker EB; Becker JC
    Hautarzt; 1998 Oct; 49(10):770-3. PubMed ID: 9857252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
    Elsässer-Beile U; Garbe C; Stadler R; Drews H; Schöpf E
    Hautarzt; 1989 May; 40(5):266-70. PubMed ID: 2737901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Fecher LA; Flaherty KT
    J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
    Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
    Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
    Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W
    Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782
    [No Abstract]   [Full Text] [Related]  

  • 20. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.